Marktanalyse - Traumatic Brain Injury - Pipeline Review, H1 2017

Global Markets Direct
02.2017
259 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Traumatic Brain Injury - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury — Pipeline Review, H1 2017, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 3, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Traumatic Brain Injury - Overview 9

Traumatic Brain Injury - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 16

Products under Development by Companies 17

Products under Development by Universities/Institutes 21

Traumatic Brain Injury - Therapeutics Assessment 22

Assessment by Target 22

Assessment by Mechanism of Action 26

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Traumatic Brain Injury - Companies Involved in Therapeutics Development 34

ALSP Inc 34

Amarantus Bioscience Holdings Inc 34

Apollo Endosurgery Inc 35

Athersys Inc 35

Beech Tree Labs Inc 36

Cognosci Inc 36

Eustralis Pharmaceuticals Ltd 37

Intellect Neurosciences Inc 37

International Stem Cell Corp 38

Ischemix Inc 38

Karyopharm Therapeutics Inc 39

Kyorin Pharmaceutical Co Ltd 39

Levolta Pharmaceuticals Inc 40

Lixte Biotechnology Holdings Inc 40

MandalMed Inc 41

Mapreg SAS 41

Neuralstem Inc 42

Neuren Pharmaceuticals Ltd 42

Neurofx Inc 43

NeuroNascent Inc 43

NeuroVive Pharmaceutical AB 44

New World Laboratories Inc 44

NuvOx Pharma LLC 45

Omeros Corp 45

Oxeia Biopharmaceuticals Inc 46

PharmatrophiX Inc 46

Phylogica Ltd 47

Prevacus Inc 47

QR Pharma Inc 48

RegeneRx Biopharmaceuticals Inc 48

Remedy Pharmaceuticals Inc 49

Sage Therapeutics Inc 49

SanBio Inc 50

STATegics Inc 50

Stemedica Cell Technologies Inc 51

SynZyme Technologies LLC 51

Tetra Discovery Partners LLC 52

Thera Neuropharma Inc 52

vasopharm GmbH 53

VG Life Sciences Inc 53

Traumatic Brain Injury - Drug Profiles 54

(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 54

2-DG - Drug Profile 55

ALP-496 - Drug Profile 57

AMRS-001 - Drug Profile 59

AST-002 - Drug Profile 68

AST-004 - Drug Profile 69

AVL-8168 - Drug Profile 70

BQ-A - Drug Profile 71

brexanolone - Drug Profile 72

BTL-slo - Drug Profile 81

Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 83

CEVA-101 - Drug Profile 84

CEVA-102 - Drug Profile 86

CHEC-9 - Drug Profile 87

CMX-2043 - Drug Profile 88

CNB-001 - Drug Profile 91

COG-1410 - Drug Profile 93

cyclosporine - Drug Profile 95

dexamethasone acetate + melatonin - Drug Profile 101

EPO-Variant - Drug Profile 102

EUC-001 - Drug Profile 103

felbamate - Drug Profile 104

glyburide - Drug Profile 105

HBI-002 - Drug Profile 109

HBI-137 - Drug Profile 110

HBN-1 - Drug Profile 111

HBN-2 - Drug Profile 112

HPI-201 - Drug Profile 113

HPI-363 - Drug Profile 115

ibudilast - Drug Profile 116

ICCN-100 - Drug Profile 126

ISC-hpNSC - Drug Profile 127

JM-4 - Drug Profile 132

KPT-350 - Drug Profile 133

LB-201 - Drug Profile 135

LB-205 - Drug Profile 136

LM-22A4 - Drug Profile 137

LM11A-31BHS - Drug Profile 139

Lpathomab - Drug Profile 141

MAP-4343 - Drug Profile 144

Monoclonal Antibody for Central Nervous System - Drug Profile 145

Monoclonal Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders - Drug Profile 146

Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile 147

MW-151 - Drug Profile 148

N-acetyl cysteine amide - Drug Profile 149

ND-478 - Drug Profile 150

Neu-2000 - Drug Profile 151

neuregulin-1 - Drug Profile 153

NFx-101 - Drug Profile 154

NNI-370 - Drug Profile 155

NNZ-2591 - Drug Profile 156

NSI-189 - Drug Profile 158

NSI-566 - Drug Profile 163

NVX-108 - Drug Profile 171

NVX-428 - Drug Profile 172

NWL-53 - Drug Profile 173

NYX-2925 - Drug Profile 174

OXE-103 - Drug Profile 176

PEG-HCC - Drug Profile 177

PF-05285401 - Drug Profile 178

Posiphen - Drug Profile 189

PRV-002 - Drug Profile 192

PYC-35 - Drug Profile 193

PYC-36 - Drug Profile 194

PYC-38 - Drug Profile 195

PYC-98 - Drug Profile 196

R-554 - Drug Profile 197

RGN-352 - Drug Profile 198

ronopterin - Drug Profile 202

SanFlow - Drug Profile 204

SB-623 - Drug Profile 205

Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 209

Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 210

Small Molecules for Traumatic Brain Injury - Drug Profile 211

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 212

Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 213

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 214

Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 220

STSE-15 - Drug Profile 221

SYN-2 - Drug Profile 223

SYN-NCE - Drug Profile 224

T-094 - Drug Profile 225

TauC-3 - Drug Profile 226

UH-0113 - Drug Profile 228

UH-0213 - Drug Profile 229

VG-1177 - Drug Profile 230

VitalHeme - Drug Profile 232

VOLT-02 - Drug Profile 233

XN-001 - Drug Profile 234

ZL-006 - Drug Profile 235

Traumatic Brain Injury - Dormant Projects 236

Traumatic Brain Injury - Discontinued Products 239

Traumatic Brain Injury - Product Development Milestones 240

Featured News & Press Releases 240

Appendix 252

Methodology 252

Coverage 252

Secondary Research 252

Primary Research 252

Expert Panel Validation 252

Contact Us 252

Disclaimer 253





List of Tables

Number of Products under Development for Traumatic Brain Injury, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Traumatic Brain Injury - Pipeline by ALSP Inc, H1 2017

Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Traumatic Brain Injury - Pipeline by Apollo Endosurgery Inc, H1 2017

Traumatic Brain Injury - Pipeline by Athersys Inc, H1 2017

Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H1 2017

Traumatic Brain Injury - Pipeline by Cognosci Inc, H1 2017

Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1 2017

Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H1 2017

Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H1 2017

Traumatic Brain Injury - Pipeline by Ischemix Inc, H1 2017

Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H1 2017

Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H1 2017

Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Traumatic Brain Injury - Pipeline by MandalMed Inc, H1 2017

Traumatic Brain Injury - Pipeline by Mapreg SAS, H1 2017

Traumatic Brain Injury - Pipeline by Neuralstem Inc, H1 2017

Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017

Traumatic Brain Injury - Pipeline by Neurofx Inc, H1 2017

Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H1 2017

Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2017

Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H1 2017

Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H1 2017

Traumatic Brain Injury - Pipeline by Omeros Corp, H1 2017

Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H1 2017

Traumatic Brain Injury - Pipeline by PharmatrophiX Inc, H1 2017

Traumatic Brain Injury - Pipeline by Phylogica Ltd, H1 2017

Traumatic Brain Injury - Pipeline by Prevacus Inc, H1 2017

Traumatic Brain Injury - Pipeline by QR Pharma Inc, H1 2017

Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals Inc, H1 2017

Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H1 2017

Traumatic Brain Injury - Pipeline by SanBio Inc, H1 2017

Traumatic Brain Injury - Pipeline by STATegics Inc, H1 2017

Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H1 2017

Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H1 2017

Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2017

Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H1 2017

Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2017

Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H1 2017

Traumatic Brain Injury - Dormant Projects, H1 2017

Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..1), H1 2017

Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..2), H1 2017

Traumatic Brain Injury - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Traumatic Brain Injury, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus